← Human Trials & Peer-Reviewed Studies
Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy
Plain-language guide to PMID 23984793 (2013): double-blind randomized controlled trial study of Exenatide in 174 patients.
Key Facts
- PMID
- 23984793
- Journal
- Canadian journal of physiology and pharmacology
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Derosa G et al. (9 authors)
- DOI
- 10.1139/cjpp-2012-0300
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exenatide in this randomized controlled trial publication.
The aim of this study was to evaluate the effects of exenatide on levels of serum adipocytokines and on β-cell function.
The researchers used ELISA methods to assess the various parameters.
Why It Was Studied
The study was conducted between 2008 and 2012.
The researchers evaluated body mass index (BMI), blood pressure, glycemic control, lipid profile, fasting plasma insulin (FPI), HOMA-IR, HOMA-β, fasting plasma proinsulin (FPPr), proinsulin : fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, retinol binding protein-4 (RBP-4), visfatin, omentin-1, and microalbuminuria.
Who Took Part
According to the abstract, 174 patients were involved.
The age groups tagged for this paper are middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.
Blinding on both sides kept the patients and researchers unaware of who received Exenatide.
Some patients received a placebo instead of Exenatide, giving a reference point.
The methods mention a period of 12 months.
What Was Measured
The researchers evaluated body mass index (BMI), blood pressure, glycemic control, lipid profile, fasting plasma insulin (FPI), HOMA-IR, HOMA-β, fasting plasma proinsulin (FPPr), proinsulin : fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, retinol binding protein-4 (RBP-4), visfatin, omentin-1, and microalbuminuria.
PubMed files the paper under topics including Adipokines, Analysis of Variance, Biomarkers, Blood Glucose, Body Mass Index, Chi-Square Distribution and Diabetes Mellitus, Type 2.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 174 patients over 12 months.
The publication is from 2013 (Canadian journal of physiology and pharmacology), a journal based in Canada.
More context: the Exenatide compound page, all human trials.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.